WO2025252101 - CAMPTOTHECIN COMPOUND AND USE THEREOF
National phase entry is expected:
Publication Number
WO/2025/252101
Publication Date
11.12.2025
International Application No.
PCT/CN2025/098942
International Filing Date
04.06.2025
Title **
[English]
CAMPTOTHECIN COMPOUND AND USE THEREOF
[French]
COMPOSÉ DE CAMPTOTHÉCINE ET SON UTILISATION
[Chinese]
一种喜树碱类化合物及其用途
Applicants **
REMEGEN CO., LTD.
Inventors
FANG, Jianmin
WANG, Zhulun
ZHANG, Wei
LIANG, Xin
ZHAN, Xiuzhi
LIU, Shangyi
TIAN, Jinlong
TANG, Haizhou
JU, Zemin
WANG, Hui
ZHANG, Qinbin
YE, Hui
LUO, Wenting
Priority Data
202410725733.5
05.06.2024
CN
202510251481.1
03.03.2025
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3603 | |
| EPO | Filing, Examination, Granting | 37412 | |
| Japan | Filing, Examination, Granting | 3359 | |
| South Korea | Filing, Examination, Granting | 4762 | |
| USA | Filing, Examination, Granting | 11990 |
Total:
61,126
Contact Us
Abstract[English]
Disclosed are a novel camptothecin compound, a linker-camptothecin compound, and a use thereof in a ligand-drug conjugate. Specifically, the involved camptothecin compound and an antibody-drug conjugate prepared therefrom can produce relatively good inhibitory activity on tumors in vivo and in vitro and exhibit significant toxicity and efficacy; in addition, a suitable metabolic rate also provides sufficient safety guarantee. These advantages are of great value for the development of antibody-drug conjugates in clinical treatment.[French]
Sont divulgués un nouveau composé de camptothécine, un composé lieur-camptothécine et son utilisation dans un conjugué ligand-médicament. Plus particulièrement, le composé de camptothécine divulgué et un conjugué anticorps-médicament préparé à partir de celui-ci peuvent produire une activité inhibitrice relativement bonne sur des tumeurs in vivo et in vitro et présentent une toxicité et une efficacité significatives ; en outre, un taux métabolique approprié fournit également une garantie de sécurité suffisante. Ces avantages sont d'une grande valeur pour le développement de conjugués anticorps-médicament dans un traitement clinique.[Chinese]
一种新型的喜树碱类化合物、连接子-喜树碱类化合物及其在配体-药物偶联物中的应用，具体涉及的喜树碱类化合物及其制备的抗体药物偶联物在体内外对肿瘤均可产生较好的抑制活性，展现出显著的毒性和药效，同时合适的代谢速率也提供了足够的安全性保障，以上优势对于抗体药物偶联物在临床治疗中的发展具有重大价值。